Shilpa Medicare Future Growth
Future criteria checks 0/6
Wir verfügen derzeit nicht über ausreichende Analystenabdeckung, um Wachstum und Umsatz für Shilpa Medicare zu prognostizieren.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Pharmaceuticals earnings growth | 18.8% |
Revenue growth rate | n/a |
Future return on equity | n/a |
Analyst coverage | None |
Last updated | n/a |
Recent future growth updates
Recent updates
Shilpa Medicare Limited's (NSE:SHILPAMED) Shares Climb 28% But Its Business Is Yet to Catch Up
Feb 21Shilpa Medicare (NSE:SHILPAMED) Takes On Some Risk With Its Use Of Debt
Jan 02These 4 Measures Indicate That Shilpa Medicare (NSE:SHILPAMED) Is Using Debt Extensively
Jul 17Shilpa Medicare (NSE:SHILPAMED) Seems To Be Using A Lot Of Debt
Mar 17Increases to CEO Compensation Might Be Put On Hold For Now at Shilpa Medicare Limited (NSE:SHILPAMED)
Sep 22Shilpa Medicare's (NSE:SHILPAMED) Dividend Will Be ₹1.10
Sep 07Shilpa Medicare's (NSE:SHILPAMED) Dividend Will Be ₹1.10
Aug 14Here's Why Shilpa Medicare (NSE:SHILPAMED) Is Weighed Down By Its Debt Load
Jan 27Shareholders May Not Be So Generous With Shilpa Medicare Limited's (NSE:SHILPAMED) CEO Compensation And Here's Why
Sep 21Does Shilpa Medicare (NSE:SHILPAMED) Have A Healthy Balance Sheet?
Jun 17If You Like EPS Growth Then Check Out Shilpa Medicare (NSE:SHILPAMED) Before It's Too Late
May 31Shilpa Medicare Limited's (NSE:SHILPAMED) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
Mar 07Shilpa Medicare Limited (NSE:SHILPAMED) Analysts Are Reducing Their Forecasts For Next Year
Feb 20Does Shilpa Medicare (NSE:SHILPAMED) Have A Healthy Balance Sheet?
Jan 26Here's Why I Think Shilpa Medicare (NSE:SHILPAMED) Is An Interesting Stock
Jan 14Shilpa Medicare (NSE:SHILPAMED) Shareholders Have Enjoyed A 54% Share Price Gain
Jan 03Could The Shilpa Medicare Limited (NSE:SHILPAMED) Ownership Structure Tell Us Something Useful?
Dec 22Is There More To The Story Than Shilpa Medicare's (NSE:SHILPAMED) Earnings Growth?
Dec 11How Much Are Shilpa Medicare Limited (NSE:SHILPAMED) Insiders Taking Off The Table?
Nov 30How Is Shilpa Medicare's (NSE:SHILPAMED) CEO Compensated?
Nov 16Earnings Release: Here's Why Analysts Cut Their Shilpa Medicare Limited (NSE:SHILPAMED) Price Target To ₹611
Nov 04Could The Market Be Wrong About Shilpa Medicare Limited (NSE:SHILPAMED) Given Its Attractive Financial Prospects?
Oct 27Is Now The Time To Put Shilpa Medicare (NSE:SHILPAMED) On Your Watchlist?
Oct 12Does Shilpa Medicare (NSE:SHILPAMED) Have A Healthy Balance Sheet?
Sep 24Shilpa Medicare (NSE:SHILPAMED) Shareholders Booked A 97% Gain In The Last Year
Sep 10Have Shilpa Medicare Limited (NSE:SHILPAMED) Insiders Been Selling Their Stock?
Aug 27What Is The Ownership Structure Like For Shilpa Medicare Limited (NSE:SHILPAMED)?
Aug 26In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Shilpa Medicare has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2023 | 11,248 | -7 | N/A | N/A | N/A |
9/30/2023 | 11,008 | -119 | -30 | 2,523 | N/A |
6/30/2023 | 10,491 | -321 | N/A | N/A | N/A |
3/31/2023 | 10,517 | -325 | -464 | 2,262 | N/A |
12/31/2022 | 11,286 | 51 | N/A | N/A | N/A |
9/30/2022 | 11,384 | 213 | -1,605 | 1,666 | N/A |
6/30/2022 | 11,693 | 599 | N/A | N/A | N/A |
3/31/2022 | 11,469 | 607 | -2,267 | 1,051 | N/A |
12/31/2021 | 10,135 | 395 | N/A | N/A | N/A |
9/30/2021 | 9,324 | 376 | -2,589 | 478 | N/A |
6/30/2021 | 9,156 | 631 | N/A | N/A | N/A |
3/31/2021 | 9,016 | 1,478 | -3,073 | 469 | N/A |
12/31/2020 | 9,135 | 1,739 | N/A | N/A | N/A |
9/30/2020 | 9,591 | 2,213 | -2,704 | 793 | N/A |
6/30/2020 | 9,698 | 2,267 | N/A | N/A | N/A |
3/31/2020 | 9,082 | 1,562 | -2,249 | 1,244 | N/A |
12/31/2019 | 8,876 | 1,455 | N/A | N/A | N/A |
9/30/2019 | 8,241 | 1,029 | -3,065 | 819 | N/A |
6/30/2019 | 6,962 | 944 | N/A | N/A | N/A |
3/31/2019 | 7,337 | 1,123 | -1,532 | 1,468 | N/A |
12/31/2018 | 7,693 | 1,193 | N/A | N/A | N/A |
9/30/2018 | 7,814 | 1,281 | N/A | N/A | N/A |
6/30/2018 | 8,211 | 1,167 | N/A | N/A | N/A |
3/31/2018 | 7,894 | 1,052 | -931 | 449 | N/A |
12/31/2017 | 7,756 | 1,133 | N/A | N/A | N/A |
9/30/2017 | 7,731 | 1,149 | N/A | N/A | N/A |
6/30/2017 | 7,787 | 1,190 | N/A | N/A | N/A |
3/31/2017 | 7,795 | 1,076 | N/A | 375 | N/A |
12/31/2016 | 7,565 | 1,048 | N/A | N/A | N/A |
9/30/2016 | 7,735 | 1,153 | N/A | N/A | N/A |
6/30/2016 | 7,369 | 1,024 | N/A | N/A | N/A |
3/31/2016 | 7,166 | 1,083 | N/A | 1,287 | N/A |
12/31/2015 | 6,867 | 886 | N/A | N/A | N/A |
9/30/2015 | 6,430 | 776 | N/A | N/A | N/A |
6/30/2015 | 6,234 | 728 | N/A | N/A | N/A |
3/31/2015 | 6,138 | 737 | N/A | 688 | N/A |
12/31/2014 | 6,145 | 731 | N/A | N/A | N/A |
9/30/2014 | 6,143 | 798 | N/A | N/A | N/A |
6/30/2014 | 5,966 | 787 | N/A | N/A | N/A |
3/31/2014 | 5,714 | 757 | N/A | 700 | N/A |
12/31/2013 | 5,025 | 664 | N/A | N/A | N/A |
9/30/2013 | 4,422 | 556 | N/A | N/A | N/A |
6/30/2013 | 3,965 | 536 | N/A | N/A | N/A |
Analyst Future Growth Forecasts
Einkommen vs. Sparrate: Unzureichende Daten, um festzustellen, ob das prognostizierte Gewinnwachstum von SHILPAMED über der Sparquote liegt (6.7%).
Ertrag vs. Markt: Unzureichende Daten, um festzustellen, ob die Gewinne von SHILPAMED schneller wachsen werden als der Markt Indian
Hohe Wachstumserträge: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von SHILPAMED in den nächsten 3 Jahren signifikant steigen werden.
Einnahmen vs. Markt: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von SHILPAMED schneller wachsen werden als der Markt von Indian.
Hohe Wachstumseinnahmen: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Einnahmen von SHILPAMED schneller wachsen werden als 20% pro Jahr.
Earnings per Share Growth Forecasts
Future Return on Equity
Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von SHILPAMED in 3 Jahren voraussichtlich hoch sein wird